Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Clariant    CLN   CH0012142631

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Clariant : launches amide/amine-free anti-static concentrate for cleanroom and pharma sectors

share with twitter share with LinkedIn share with facebook
share via e-mail
09/28/2017 | 06:59pm CEST

Specialty chemicals producer Clariant has produced a new amide/amine-free anti-static masterbatch concentrate for polyethylene films used in pharmaceutical production. The new anti-stat, marketed as MEVOPUR PEAM 176045, will be introduced at CPhI Worldwide, being held 24-26 October 2017 at Messe Frankfurt.

The introduction is timely due to the changes in industry standards which, by 2020, will limit the acceptability of many of the currently used films that contain amide- and amine-based anti-stats, says Stephen Duckworth, Clariants Head of Global Segment Medical and Pharmaceutical. For the first time, plastics used in pharma manufacturing, including anti-static films, will need to comply with the same standards as plastics packaging used for finished pharmaceuticals.

Anti-static additives are routinely incorporated in the polyethylene cleanroom films that line containers and dispensers for active pharmaceutical ingredients (APIs), and in the tubes used to transfer powdered and liquid API during drug production. They are important because the anti-static properties help to reduce the risk of dangerous conditions like explosions, he explained.

The new additive masterbatch concentrate is part of MEVOPUR, Clariant`s brand of Controlled, Consistent and Compliant products for plastics applications in the medical and pharmaceutical industries.

When incorporated into polyethylene (PE) films Clariants new anti-static provides "very good static-dissipating performance and a competitive cost profile relative to alternatives," says the company. In addition, it has already been tested to the stricter new United States Pharmacopeia (USP) pharmaceutical standard for pharmaceutical-contacting plastics, which are scheduled to come into force in 2020.

The new standard USP Plastic Components and Systems Used in the Manufacturing of Drug Products will, for the first time, apply the same risk-based assessment of materials. Plastic components and single-use containers are increasingly used in manufacturing processes, particularly biological manufacturing processes. Despite their advantages, these plastic assemblies elicit concerns about chemical compounds that may leach or migrate into finished products and impact product quality or safety.

Historically, these anti-static films have predominantly relied on migrating ethoxylated amine/amide-based anti-stats that had a degree of compliance to regulations for food contacting materials. Risk assessments that define migration limits applying to these additives cut allowable addition rates for amide- and amine-based additives to levels below of what is required for effective anti-static performance. This, in addition to the need to test at lower humidity levels (e.g. below 25%), increasingly constrains these current technologies.

Existing products, often produced to a food-contact standard, fall short of new and more stringent standards, Clariants new PEAM 176045 additive concentrate becomes an ideal alternative, Duckworth asserts. It is fast-acting and long-lasting and amide/amine-free. It performs even at the low relative-humidity levels common to pharmaceutical cleanrooms. And, compared to other alternatives, including permanent or non-migrating additives, such as polyether block amide (PEBA), it can be effectively used at a far lower concentration and cost.

This is a product that film producers can adopt with an eye on present issues with migration limits and to the future, he adds, noting that Clariants MEVOPUR PEAM 176045 has been tested to support compliance with the upcoming USP changes, and has none of the migration-limit concerns.

As part of the MEVOPUR product line, the PEAM 176045 anti-stats are immediately available with declarations based on biological evaluation of raw materials per ISO 10993-4, -5, -10, 11 and USP, class VI. European Pharmacopeia and USP 661.1.

This data, along with a ISO13485-based manufacturing/quality process, full change-control procedures, and documentation such as Drug Master File, help support the risk-management process of medical device producers. MEVOPUR Controlled, Consistent and Compliant colour and additive masterbatch concentrates and fully compounded plastics help manufacturers in the medical and pharmaceutical sectors control and minimise risk, while responding quickly to changing industry standards.

Besides the presence of Healthcare Polymer Solutions at CPhI 2017, please join also the experts from Clariants Business Unit Industrial & Consumer Specialties in meeting room Inspiration 1 in hall 10.2 to discuss and learn about Polyglykol and the Macrogol range.

(c) 2017 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CLARIANT
07:12aCLARIANT : Unveils Controlled-Atmosphere Packaging Solutions at CPhI Middle East..
07/18CLARIANT : expands partnership with Lintech International LLC in the United Stat..
07/17CLARIANT : ColorForward® 2019 Inspires Mold-Texture Specialist
07/04CLARIANT : expands EnviCat catalyst portfolio for selective catalytic reduction ..
07/03CLARIANT : MILITARY USAF Awards Contract to Reliant Aluminum Products for Chemic..
07/03CLARIANT : expands EnviCat catalyst portfolio for selective catalytic reduction ..
06/26CLARIANT : enhances capabilities at Clinton, Oklahoma facility
06/26CLARIANT : extends EnviCat® catalyst portfolio to offer extruded SCR NOx solutio..
More news
News from SeekingAlpha
06/08Clariant (CLZNY) Presents At Credit Suisse 2018 Global Chemicals And Agricult.. 
04/25Clariant (CLZNF) Q1 2018 Results - Earnings Call Transcript 
04/25Clariant beats by CHF 3.4M on EBITDA, beats on revenue 
04/25Clariant AG 2018 Q1 - Results - Earnings Call Slides 
02/23Tracking Alex Roepers' Atlantic Investment Management Portfolio - Q4 2017 Upd.. 
Financials (CHF)
Sales 2018 6 713 M
EBIT 2018 737 M
Net income 2018 429 M
Debt 2018 1 454 M
Yield 2018 2,24%
P/E ratio 2018 18,86
P/E ratio 2019 16,83
EV / Sales 2018 1,40x
EV / Sales 2019 1,31x
Capitalization 7 914 M
Duration : Period :
Clariant Technical Analysis Chart | CLN | CH0012142631 | 4-Traders
Technical analysis trends CLARIANT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 18
Average target price 25,8  CHF
Spread / Average Target 7,2%
EPS Revisions
Hariolf Kottmann Chief Executive Officer & Executive Director
Rudolf Wehrli Chairman
Patrick Jany Chief Financial Officer
Peter Chen Non-Executive Director
Carlo G. Soave Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CLARIANT-11.78%7 870
ECOLAB7.32%41 466
SIKA AG0.00%21 002
SYMRISE9.72%11 904